KR20120110453A - Skin external composition containing myrothamnus flabellifolia callus extract - Google Patents
Skin external composition containing myrothamnus flabellifolia callus extract Download PDFInfo
- Publication number
- KR20120110453A KR20120110453A KR1020110028322A KR20110028322A KR20120110453A KR 20120110453 A KR20120110453 A KR 20120110453A KR 1020110028322 A KR1020110028322 A KR 1020110028322A KR 20110028322 A KR20110028322 A KR 20110028322A KR 20120110453 A KR20120110453 A KR 20120110453A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- callus
- extract
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 206010020649 Hyperkeratosis Diseases 0.000 title claims abstract description 76
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 241001646133 Myrothamnus flabellifolia Species 0.000 title claims abstract description 12
- 230000037303 wrinkles Effects 0.000 claims abstract description 27
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 230000009759 skin aging Effects 0.000 claims abstract description 12
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 9
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 9
- 230000006872 improvement Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000037394 skin elasticity Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000037330 wrinkle prevention Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 19
- 230000003405 preventing effect Effects 0.000 abstract description 11
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 230000000622 irritating effect Effects 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 74
- 241000196324 Embryophyta Species 0.000 description 40
- 239000002537 cosmetic Substances 0.000 description 32
- 239000002609 medium Substances 0.000 description 27
- -1 patches Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000006210 lotion Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 206010051246 Photodermatosis Diseases 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000008845 photoaging Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229930192334 Auxin Natural products 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002363 auxin Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000037373 wrinkle formation Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000003617 indole-3-acetic acid Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008635 plant growth Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 2
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001646137 Myrothamnus Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 부활초(Myrothamnus flabellifolia ) 캘러스 추출물을 유효성분으로 함유하는 피부 노화 방지용 피부 외용제 조성물에 관한 것이다.
본 발명에 따른 부활초 캘러스 추출물을 함유하는 피부외용제 조성물은 천연물을 함유한 조성물로써, 합성 화학물질에 비해 인체에 무해하고, 피부에 자극적이지 않으며, 콜라겐 합성 증진 효과, 엘라스타제 억제 효능 등을 가지고 있어, 피부 주름 방지, 주름 개선 효과, 항산화 효과를 가지고 있어, 피부 노화 방지, 피부 주름 개선의 목적으로 적용가능하다.The present invention is Myrothamnus flabellifolia ) relates to a skin external composition for preventing skin aging containing an extract of callus as an active ingredient.
The composition for external application for skin containing the callus extract callus extract according to the present invention is a composition containing natural products, which is harmless to the human body compared to synthetic chemicals, is not irritating to the skin, enhances collagen synthesis, and inhibits elastase. Having anti-wrinkle, anti-wrinkle effect and antioxidant effect, it is applicable for the purpose of anti-aging of the skin and improvement of skin wrinkles.
Description
본 발명은 부활초(Myrothamnus flabellifolia ) 캘러스 추출물을 유효성분으로 함유하는 피부 노화 방지용 피부 외용제 조성물에 관한 것이다.
The present invention is Myrothamnus flabellifolia ) relates to a skin external composition for preventing skin aging containing an extract of callus as an active ingredient.
신체의 근육운동이나 관절운동이 자주 일어나는 부위에는 주름이 있어 자유롭게 움직일 수 있도록 해준다. 만약 이런 부위에 주름이 하나도 없이 팽팽하다면 우리가 신체를 자유롭게 움직이는 것은 매우 불편할 것이다. 그러나 자연노화나 광노화에 의해서 눈밑 피부가 처지고 정상적인 피부에 심한 주름이 발생하는 것은 미용적으로 좋은 인상을 주지 못한다. 이러한 주름에는 활성산소와 여러 가지 프리 라디칼이 관여한다. 이러한 광노화 현상은 자외선에 의하여 세포 내부에 활성 산소 라디칼이 생성되고, 이 활성 산소는 염증성 반응을 일으키는 신호전달 체계를 통하여 진피의 I형 콜라겐, III형 콜라겐, 표피층과 진피층 사이를 잇는 기저만(base membrane)의 IV형 콜라겐, 엘라스틴, 라미닌(laminin)의 감소나 변형, 표피진피기저막의 편평화(flattening), 단백질 분해효소(MMP-1, MMP-3, MMP-9 등)의 합성을 촉진하여 (Fisher G.J. et al., Nature, Vol. 379, 335-339) 진피층의 탄력을 감소시킴으로써 피부 주름이 유발되는 것으로 알려져 있다. 즉, 콜라겐이 감소하고 엘라스틴의 가교 결합이 증가할 뿐만 아니라 기질의 저하에 의해 피부의 탄력이 저하되고 주름이 생성되는 것이다. 주름개선 화장품에 필수적인 주름개선제로는 진피의 결합조직 형성을 촉진하는 섬유아세포의 성장을 촉진하는 물질, 섬유아세포의 콜라겐 합성을 촉진하는 물질, 활성산소와 프리라디칼을 제거하는 물질 등이 있다.Frequent areas of muscle and joint movement in the body have wrinkles that allow them to move freely. If there were no wrinkles in these areas, it would be very uncomfortable for us to move the body freely. However, the skin under the eyes due to natural aging or photo aging and severe wrinkles on the normal skin does not give a beauty impression. These wrinkles involve free radicals and various free radicals. In this photoaging phenomenon, free radicals are generated inside the cell by ultraviolet rays, and the free radicals are connected between the collagen type I, the type III collagen, the epidermal layer and the dermis layer through a signaling system causing an inflammatory reaction. Membrane type IV collagen, elastin, laminin reduction or modification, flattening epidermal basement membrane, promoting the synthesis of proteolytic enzymes (MMP-1, MMP-3, MMP-9, etc.) (Fisher GJ et al., Nature, Vol. 379, 335-339) It is known that skin wrinkles are caused by reducing the elasticity of the dermal layer. That is, collagen decreases, crosslinking of elastin increases, and the elasticity of the skin decreases and wrinkles are generated by the degradation of the substrate. Wrinkle improvement agents essential for wrinkle improvement cosmetics include substances that promote the growth of fibroblasts that promote the formation of connective tissues of the dermis, substances that promote collagen synthesis of fibroblasts, and substances that remove free radicals and free radicals.
주름살은 얼굴 부위에 가장 나타나기 쉽고 눈가나 이마 등 주름살이 나타나기 쉬운 부위의 특징에서도 알 수 있듯이 근육의 움직임에 따라 반복적으로 가해진 피부 변형이 서서히 주름살로 고정되어 형성된다. 그 과정이 분명히 밝혀져 있지 않지만 나이가 들어감에 따라 일어나는 피부의 구조기능의 변화와 깊은 관련이 있다. 만성적인 햇빛 노출이 초래하는 광노화 피부에서는 표피, 진피, 그들의 접합부, 혹은 모세혈관계 등 광범위하게 자연노화 피부와는 다른 조직학적형태학적 변화가 나타난다. Wrinkles are most likely to appear on the face, and as the features of the areas such as the eyes and foreheads where wrinkles are most likely to appear, the skin deformation repeatedly applied according to the movement of the muscles is gradually fixed to the wrinkles. The process is not clear, but it is closely related to changes in the structure of the skin as it ages. Photoaging skin caused by chronic sun exposure results in a wide range of histological and morphological changes from the natural skin, such as the epidermis, dermis, their junctions, or capillaries.
각질층의 두꺼워짐, 건조, 혹은 진피에 있어서 콜라겐의 감소나 변성된 엘라스틴의 축적, 나아가서 기저층의 변형과 그 주변의 손상 등 여러 가지 피부조직의 변화가 피부의 탄력 저하를 초래하고 반복되는 피부의 변형에 대한 복원력을 저하시켜, 이윽고 주름으로 정착하게 되는 것이다. Changes in various skin tissues, such as thickening of the stratum corneum, dryness, or reduction of collagen in the dermis, accumulation of denatured elastin, and further alteration of the basal layer and damage to the periphery, result in decreased elasticity of the skin and repeated skin deformation. It lowers the restoring force for, and will eventually settle into wrinkles.
주름과 관련된 피부의 생리적 변화 가운데 하나가 섬유아세포의 증식 감소이다. 섬유아세포의 증식이 감소되면 콜라겐 합성이 적어지고, 이것은 외부인자에 대한 방어력의 약화로 이어져 주름생성을 측진하게 된다. One of the physiological changes in skin associated with wrinkles is the reduction of fibroblast proliferation. Reduced fibroblast proliferation leads to less collagen synthesis, which leads to a weakening of the defense against external factors leading to wrinkle formation.
식물은 오래 전부터 인류 복지에 도움을 주는 다양한 천연물질들의 공급원이 되어왔다. 이들 물질들은 대부분 이차대사산물로서 의약품, 식품 첨가물, 화장품 원료, 향료, 색소 등의 용도로 사용되고 있다. 유기합성 분야의 발달에 의한 수많은 새로운 화합물들의 합성에도 불구하고 식물은 아직도 신물질의 근원으로 인정받고 있다. 매년 식물에서 발견되는 새로운 화학구조를 갖는 신물질이 수천 가지 이상이며 그 중 상당수는 생리활성을 갖고 있음을 고려한다면 식물은 중요한 원료가 된다고 할 수 있다. Plants have long been a source of various natural substances that help human well-being. Most of these substances are secondary metabolites and are used for pharmaceuticals, food additives, cosmetic raw materials, fragrances, and pigments. Despite the synthesis of numerous new compounds by the development of the field of organic synthesis, plants are still recognized as a source of new substances. Considering that there are more than a thousand new substances with new chemical structures found in plants every year, many of them are bioactive, which makes them an important ingredient.
식물은 식물을 구성하는 잎, 줄기, 뿌리 등 그 일부만을 이식하여도 전체 개체가 다시 형성되는 전형성능(totipotency)이 뛰어나다. 식물세포는 식물의 조직으로부터 유도된 미분화(undifferentiated) 세포인 캘러스(Callus)를 말하는데, 캘러스는 정상적인 기관형성이나 조직분화를 일으키는 능력을 잃은 무정형의 조직 또는 세포덩어리로서, 식물체에서 잘라낸 조직을 옥신(Auxin)이나 싸이토카인(Cytokines)을 함유한 배지에서 배양하거나 식물체에 상처를 내거나 또는 식물체의 상구를 옥신으로 처리하였을 때 생긴다. 캘러스는 식물세포 배양, 특히 조직배양을 통하여 잎, 줄기, 뿌리, 근경, 열매 등 식물의 어느 부분에서도 유도될 수 있으며, 계대배양에 의해 계속해서 만들어 낼 수 있다는 특징을 가지고 있다. Plants have an excellent totipotency in which the entire individual is formed even when only a part of the leaves, stems, and roots constituting the plant are transplanted. Plant cells are callus, undifferentiated cells derived from plant tissues. Callus is an amorphous tissue or mass of cells that has lost its ability to cause normal organogenesis or tissue differentiation. Occurs when cultured in a medium containing Auxin or Cytokines, wounding of plants, or treatment of the plant's epithelium with auxin. Callus can be derived from any part of the plant such as leaves, stems, roots, rhizomes, and fruits through plant cell culture, especially tissue culture, and is characterized by being continuously produced by subculture.
식물 세포의 배양의 기본 원칙은, 모든 식물 세포는 그 세포가 유래되는 전체 식물을 건설하는 능력을 갖는다는 생물학적 사실을 이용한다. 이 전형성능은 동물 유래의 배아줄기세포의 다분화성과 비교 가능하고, 윤리적인 문제나 안전성의 문제가 없어 화장품 분야를 포함한 다양한 분야에서 식물 줄기세포의 활용에 대한 관심이 점점 높아지고 있다. 따라서, 식물 세포가 피부 줄기 세포의 보호 및 활성화에 대한 긍정적 영향을 준다는 것을 받아들일 수 있다. 이러한 식물의 성질을 이용한 조직배양을 통한 미분화세포덩어리인 캘러스 배양을 이용한다면 우수한 생리활성 효능을 지닌 화장품 원료로서의 가치가 있다고 볼 수 있다. The basic principle of the cultivation of plant cells takes advantage of the biological fact that every plant cell has the ability to build the whole plant from which the cell is derived. This pluripotency is comparable to the diversity of animal-derived embryonic stem cells, and there is no ethical problem or safety problem, and thus the interest in the use of plant stem cells in various fields including cosmetics is increasing. Thus, it can be accepted that plant cells have a positive effect on the protection and activation of skin stem cells. If callus culture, which is an undifferentiated cell mass through tissue culture using the properties of these plants, is used, it can be regarded as valuable as a cosmetic raw material having excellent physiological activity.
따라서, 이러한 기술분야의 흐름에 따라, 본 발명자들은 부활초 추출물이 항노화 효과가 있음을 확인하고 본 발명을 완성하였다.
Therefore, according to the flow of this technical field, the present inventors confirmed that the revival flower extract has an anti-aging effect and completed the present invention.
따라서, 본 발명의 목적은 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 외용제 조성물을 제공하는데 있다. Accordingly, it is an object of the present invention to provide a composition for external application for skin containing an active plant callus extract as an active ingredient.
본 발명의 다른 목적은, 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 노화 방지용 피부 외용제 조성물을 제공하는데 있다.Another object of the present invention is to provide a skin external preparation composition for preventing skin aging containing an active plant callus extract as an active ingredient.
본 발명의 또 다른 목적은, 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 탄력증진용 피부 외용제 조성물을 제공하는데 있다.Still another object of the present invention is to provide a skin external preparation composition for skin elasticity, which contains an active plant callus extract as an active ingredient.
본 발명의 또 다른 목적은, 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 주름 형성 예방 및 피부 주름 개선용 피부 외용제 조성물을 제공하는데 있다.Still another object of the present invention is to provide a skin external preparation composition for preventing skin wrinkle formation and improving skin wrinkles, which contains an active plant callus extract as an active ingredient.
본 발명의 또 다른 목적은, 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 탄력증진용 피부 외용제 조성물을 제공하는데 있다.Still another object of the present invention is to provide a skin external preparation composition for skin elasticity, which contains an active plant callus extract as an active ingredient.
본 발명의 또 다른 목적은, 부활초 캘러스 추출물을 유효성분으로 함유하는 항산화능을 가지는 피부 외용제 조성물을 제공하는데 있다.
Still another object of the present invention is to provide an external preparation composition for skin having an antioxidant activity containing an active plant callus extract as an active ingredient.
상기의 목적을 달성하기 위해, 본 발명은 부활초 (Myrothamnus flabellifolia) 캘러스 추출물을 유효성분으로 함유하는 피부 외용제 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for external application to the skin containing Myrothamnus flabellifolia callus extract as an active ingredient.
또한, 본 발명은 부활초 캘러스 추출물을 조성물의 총 중량에 대하여 0.1 내지 10중량%를 함유하는 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle A skin external preparation composition containing the callus extract in an amount of 0.1 to 10% by weight based on the total weight of the composition.
또한, 본 발명은 상기 부활초 캘러스 추출물은 분말화하여 조성물에 함유된 것을 특징으로 하는 피부 외용제 조성물을 제공한다.In addition, the present invention provides a composition for external application to the skin, characterized in that the revival of the callus extract powdered contained in the composition.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 피부 노화 방지용 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle Provided is a skin external composition for preventing skin aging containing a callus extract.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 피부 탄력증진용 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle Provided is a skin external preparation composition for enhancing skin elasticity containing a callus extract.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 피부 주름 형성 예방 및 피부 주름 개선용 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle Provided is a skin external preparation composition for preventing skin wrinkle formation and improving skin wrinkles containing callus extract.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 항산화능을 가지는 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle Provided is an external composition for skin having an antioxidant activity containing a callus extract.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 콜라겐 합성 증진능을 가지는 피부 외용제 조성물을 제공한다.In addition, the present invention is resurrection candle Provided is an external composition for skin having a collagen synthesis enhancing ability containing a callus extract.
또한, 본 발명은 부활초 캘러스 추출물을 함유하는 엘라스타제 억제능을 가지는 피부 외용제 조성물을 제공한다.
In addition, the present invention is resurrection candle Provided is an external preparation composition for skin having an elastase inhibitor containing a callus extract.
본 발명에 따른 부활초 캘러스 추출물을 함유하는 피부외용제 조성물은 천연물을 함유한 조성물로써, 합성 화학물질에 비해 인체에 무해하고, 피부에 자극적이지 않으며, 콜라겐 합성 증진 효과, 엘라스타제 억제 효능 등을 가지고 있어, 피부 주름 방지, 주름 개선 효과, 항산화 효과를 가지고 있어, 피부 노화 방지, 피부 주름 개선의 목적으로 적용가능하다.
The composition for external application for skin containing the callus extract callus extract according to the present invention is a composition containing natural products, which is harmless to the human body compared to synthetic chemicals, is not irritating to the skin, enhances collagen synthesis, and inhibits elastase. Having anti-wrinkle, anti-wrinkle effect and antioxidant effect, it is applicable for the purpose of anti-aging of the skin and improvement of skin wrinkles.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법 은 본 기술분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
본 발명의 상세한 설명 등에서 사용되는 주요 용어의 정의는 다음과 같다. Definitions of main terms used in the detailed description of the present invention are as follows.
본 발명에 있어서, "추출물"은 상기 부활초 캘러스 자체 또는 부활초 캘러스를 분말화하거나, 열수추출법, 에탄올 추출법 등에 의해 수득한 추출물을 의미한다. In the present invention, "extract" refers to an extract obtained by pulverizing the resurrection plant callus itself or resurrection plant callus, hot water extraction method, ethanol extraction method and the like.
본 발명에 있어서, "유효성분으로 함유하는"의 의미는, 피부 외용제 조성물로써 피부 노화 방지 효과, 피부 주름 예방, 피부 주름 개선, 항산화 효과, 콜라겐 합성 증진효과, 엘라스타제 억제 효과, 세포 증식능을 나타낼 수 있을 정도로 함유하는 것을 의미한다. In the present invention, the meaning of "contained as an active ingredient" means a skin external preparation composition for preventing skin aging, preventing skin wrinkles, improving skin wrinkles, antioxidant effects, enhancing collagen synthesis, inhibiting elastase, and increasing cell proliferation. It means to contain enough to show.
본 발명에 있어서, "캘러스"는 식물체에서 잘라낸 조직을 옥신을 함유한 배지에서 배양하거나, 어떤 종류의 식물에 상처를 내거나, 상구를 옥신으로 처리하거나 할 때에 생기는 특수한 조직 또는 세포덩어리를 말한다. 보통 캘러스는 정상적인 기관형성이나 조직분화를 일으키는 능력을 잃은 무정형의 조직 또는 세포덩어리로 대부분 유세포로 되어 있다. 넓은 의미로는 아그로박테리움(agrobacterium) 등의 감염에 의해서 생기는 식물종양조직도 포함시키기도 한다.In the present invention, "callus" refers to a special tissue or a mass of cells generated when a tissue cut out of a plant is cultured in an auxin-containing medium, a certain kind of plant is wounded, or an upper mouth is treated with auxin. Normally, callus is an amorphous tissue or cell mass that has lost its ability to cause normal organogenesis or tissue differentiation, and is mostly composed of flow cells. In a broad sense, it may also include plant tumor tissue caused by infections such as agrobacterium.
조직배양을 통한 미분화세포덩어리인 캘러스가 형성되면, 즉, 식물체내의 세포는 증식하면 즉시 방향이 정해져서 특정한 조직 더 나아가서는 기관으로 규칙적으로 조립되어 간다. 그러나, 다양한 식물 성장 호르몬 등을 외부로부터 주게 되면 그때까지 유지되어 왔던 통제가 해제되어 세포가 제멋대로 증식하는 것으로 해석된다.When callus, which is a mass of undifferentiated cells through tissue culture, is formed, that is, the cells in a plant are directed immediately after proliferation, and are assembled regularly into specific tissues and organs. However, when various plant growth hormones are given from the outside, the control that has been maintained until then is released, and cells are interpreted to proliferate arbitrarily.
탈분화에 의해 얻어진 캘러스를 같은 조성을 가진 액체배지에 넣어서 진탕배양하면 세포는 따로 떨어져 현탁 상태로서 증식을 계속한다. 이 캘러스나 배양세포는 새로운 배지에 계대 배양함으로써 영구적으로 분열 및 증식할수 있게 되어 완전 식물체가 노화해서 죽어가는 분화세포와는 본질적으로 차이가 있다. 몇 세대정도 계대 배양한 캘러스 또는 배양세포를 다양한 식물 성장 호르몬을 제거한 고형 배지에 도포해두면 눈과 뿌리가 나와서 개체 식물이 복원된다. 이 재생식물은 한 개의 배양세포의 분열증식에서 유래한 것이며, 그 배양세포의 근원을 말하면 배축이나 수조직에서 유도한 것이다. 다시 말하면, 식물체를 구성하는 한 개의 체세포에서 식물이 복원한다는 것이다. 원래의 식물체는 몇 억 개의 체세포로 구성되어 있고, 그 모든 것이 생식세포와 같은 개체를 창조하는데 필요한 유전자를 모두 갖추고 있다는 것을 의미한다. 모식물체로부터 분리된 식물조직세포는 적정배양환경에서 배양하면 완전한 식물체로 재생될 수 있는 잠재력 즉, 전형성능을 가지고 있다. 이 전형성능은 식물 발생학 등의 학술적인 중요성은 물론이지만 화장품 원료 등의 실용화를 위해서도 활용가치가 크다.When the callus obtained by dedifferentiation is added to a liquid medium having the same composition and shaken, the cells are separated and continue to proliferate as a suspended state. The callus or cultured cells are essentially different from the differentiated cells in which complete plants age and die because they can be permanently divided and proliferated by passage in fresh medium. Callus or cultured cells, which have been passaged for several generations, are applied to a solid medium from which various plant growth hormones have been removed. This regenerated plant is derived from the division and proliferation of a single cultured cell, and the source of the cultured cell is derived from axons or aquatic tissues. In other words, the plant is restored in one somatic cell that makes up the plant. The original plant is made up of billions of somatic cells, all of which contain all the genes needed to create a germ-like individual. Plant tissue cells isolated from the parent plants have the potential to be regenerated into complete plants when cultured in an appropriate culture environment. This morphogenic ability is of great value for the practical use of cosmetic raw materials, as well as for academic importance such as plant development.
본 발명에 있어서, "부활초 캘러스"는 부활초의 어느 부위로부터 유도된 것이든 모두 가능하나, 일 구체예로, 부활초 종자의 발아된 유묘로부터 자엽을 절취하여 유도시킨 캘러스일 수 있고, 부활초의 어느 조직이든지 일부 잘라내어 옥신 및 사이토키닌의 함량을 조절한 배지에 놓아두면 캘러스가 형성될 수 있다. In the present invention, the "resurrection callus" may be any one derived from any part of the resurrection plant, but in one embodiment, may be a callus derived by cutting cotyledon from the germinated seedlings of the resurrection plant. Callus can form when any tissue is partially cut out and placed in a controlled medium containing auxin and cytokinin.
본 발명에 있어서, "피부노화"는 피부 조직의 탄력성이 저하되면서 피부가 주름지거나, 피부의 색소 침착, 피부의 탄력 감소 등 일반적으로 당업계에 알려져있는 피부 노화 상태를 모두 포함하는 개념이다. 좀 더 구체적으로, 피부 노화는 나이가 들어감에 따라 자연히 발생하는 자연노화(intrinsic aging, 내인성노화)와 주위 환경 특히 자외선에 의한 광노화(photoaging)으로 나눌 수 있다.In the present invention, "skin aging" is a concept including all skin aging conditions generally known in the art such as wrinkles of the skin, pigmentation of the skin, reduction of the elasticity of the skin, etc. while the elasticity of the skin tissue is reduced. More specifically, skin aging may be divided into natural aging (endogenous aging) that occurs naturally with age and photoaging due to the surrounding environment, particularly ultraviolet rays.
광노화(photoaging)는 오랫동안 햇빛에 노출된 얼굴, 손등, 목뒤 등의 피부에서 관찰되는 노화현상을 발하는 것으로 자연노화 현상과 자외선에 의한 영향이 합쳐진 결과로 발생한다. 자연노화와 광노화 사이에는 주름이 생성되는 기전이 세부적으로 차이가 있지만 ① 피부세포의 증식이나 신진대사가 저하되며 ② 표피-진피 사이의 결합이 약해 조그만 자극에도 손상을 입기 쉽고 ③ 콜라겐의 합성양이 감소 ④ 콜라겐 분해 효소인 MMPs(Matrix metalloproteinases)의 과다한 발현 증가등의 생리적 변화들이 나타나 피부가 건조해지며, 표피, 진피층의 구조적인 차이로 인해 탄력성을 잃어버리고, 점차적으로 주름이 깊어진다. 현재는 주름 개선과 예방을 위해 화장품 영역에서 다양한 기전의 많은 기능성 원료들이 개발되고 있는데, 대표적으로 retinol을 주성분으로 사용하는 화장품이 일반적이다. 또한, 여러 원인에 의해 발생되는 피부노화를 억제하거나 개선하기 위해 유해산소 소거 물질, MMP-1 억제나 콜라겐 생성촉진등과 같은 물질들의 개발이 필요하다.Photoaging is an aging phenomenon observed on the skin of the face, back of the hand, back of the neck, etc., which has been exposed to sunlight for a long time, and is a result of the combination of natural aging and the effects of ultraviolet rays. Wrinkle formation mechanism is different in detail between natural aging and photo aging, but ① skin cell proliferation or metabolism is deteriorated ② epidermis-dermis is weakly damaged due to weak binding ③ collagen synthesis amount Decrease ④ Physiological changes such as excessive expression of collagen degrading enzyme MMPs (Matrix metalloproteinases) increase, resulting in dry skin, loss of elasticity due to structural differences in epidermis and dermis, and gradually deepening wrinkles. Currently, many functional raw materials with various mechanisms are being developed in the cosmetics area for wrinkle improvement and prevention. Typically, cosmetics using retinol as a main ingredient are common. In addition, in order to suppress or improve skin aging caused by various causes, it is necessary to develop substances such as scavenger scavenging substances, MMP-1 inhibition or collagen production.
본 발명은 일 관점에서, 상기 부활초 캘러스 추출물을 유효성분으로 함유하는 피부 외용제 조성물에 관한 것이다.The present invention relates to an external composition for skin containing the above-mentioned revival callus extract as an active ingredient.
부활초(학명: Myrothamnus flabellifolia , 영명: Resurrection Plant)는 덤불처럼 다수의 줄기를 내며 자라는 관목으로 아프리카 중부 이남 지역에만 분포하며, 바위 도상구릉에서 자란다. 크기는 0.5~1.5 m이며, 잎은 접혀져 있으며, 떨어지지 않고 달려 있는데 극히 건조한 서식지에서도 잘 적응하여 오래도록 남아 있으나 재배되지는 않는다.Resurrection Candle ( Myrothamnus) flabellifolia , English name: Resurrection Plant) is a shrub that grows in multiple branches like bushes and is distributed only in sub-Africa and grows in rocky hills. Its size is 0.5 ~ 1.5 m, and the leaves are folded and do not fall off. They adapt well to extremely dry habitats and remain long but are not grown.
본 발명에 있어서, 상기 부활초 캘러스 추출물은 조성물의 총 중량에 대하여 0.1 내지 20중량%, 0.1 내지 15중량%, 0.1 내지 10 중량%, 0.1 내지 5 중량%, 또는 0.1 내지 1 중량%, 0.1 내지 0.5 중량%를 함유하는 것을 특징으로 할 수 있다. 상기 0.1 중량% 미만인 경우, 그 효과가 미미하며, 10중량%를 초과하는 경우 안전성과 제형 안정성의 문제점이 있다. In the present invention, the revival callus extract is 0.1 to 20% by weight, 0.1 to 15% by weight, 0.1 to 10% by weight, 0.1 to 5% by weight, or 0.1 to 1% by weight, 0.1 to the total weight of the composition It may be characterized by containing 0.5% by weight. If less than 0.1% by weight, the effect is insignificant, if more than 10% by weight there is a problem of safety and formulation stability.
다른 관점에서, 본 발명은 부활초 캘러스 추출물을 함유하는 피부 노화 방지용, 피부 탄력증진용 또는 피부 주름 형성 예방 및 피부 주름 개선용 피부 외용제 조성물에 관한 것이다. In another aspect, the present invention relates to a skin external preparation composition for preventing skin aging, skin elasticity or preventing skin wrinkle formation and improving skin wrinkles, which contains an activated cauliflower extract.
또한, 다른 관점에서, 부활초 캘러스 추출물을 함유하는 항산화능을 가지는 조성물, 콜라겐 합성 증진능을 가지는 조성물, 엘라스타제 억제능, 또는 세포 증식능을 가지는 조성물에 관한 것이다.In another aspect, the present invention relates to a composition having an antioxidant activity, a composition having an ability to enhance collagen synthesis, an elastase inhibitory activity, or a composition having a cell proliferation ability.
또한, 본 발명에 따른 피부 외용제 조성물은 화장료 조성물 또는 약학적 조성물일 수 있다.In addition, the topical skin composition according to the present invention may be a cosmetic composition or a pharmaceutical composition.
상기 피부외용제 조성물이 약학적 조성물일 경우, 이미 공지되어 사용되고 있는 약학적으로 허용가능한 담체를 추가적으로 포함할 수 있다. 다시말해, 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제 등을 더 포함할 수 있다. When the external skin composition is a pharmaceutical composition, it may further include a pharmaceutically acceptable carrier that is already known and used. In other words, it may further include suitable carriers, excipients and diluents and the like commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학 조성물을 제공한다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition comprising the extract according to the present invention can be used in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and sterile injectable solutions, respectively, according to conventional methods. It provides a skin external pharmaceutical composition, preferably creams, gels, patches, sprays, ointments, warnings, lotions, linen, pasta or cataplasma. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 부활초 추출물을 함유하는 피부 외용제 조성물은 피부에 적용할 수 있는 피부 외용제 제형으로서 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태의 약학조성물로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다.The composition for external application for skin containing the vinegar extract of the present invention is a skin external preparation that can be applied to the skin of a cream, gel, patch, spray, ointment, warning agent, lotion agent, liniment agent, pasta agent or cataplasma agent. It may be prepared and used as a pharmaceutical composition in the form of external preparations for skin, but is not limited thereto.
본 발명에 따른 외용제 조성물이 화장료 조성물인 경우, 피부 노화 방지, 피부 주름 개선, 주름 완화, 항산화능, 피부 탄력 증진 등을 위한 화장품 및 세안제 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 각종 크림, 로션, 스킨 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다.When the external preparation composition according to the present invention is a cosmetic composition, it can be used in a variety of cosmetics and cleansing agents for preventing skin aging, skin wrinkle improvement, wrinkle relief, antioxidant capacity, skin elasticity and the like. Examples of products to which the present composition can be added include cosmetics such as various creams, lotions, skins, and the like, cleansing agents, face washes, soaps, treatments, and essences.
본 발명의 화장료 조성물은 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다. The cosmetic composition of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extracts.
본 발명의 화장료 조성물에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다. 이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition to the said essential component, you may mix | blend with the cosmetic composition of this invention the other component normally mix | blended with cosmetics as needed. Other components that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation accelerators, cooling agents, restriction agents, purified water and the like.
상기 화장료 조성물에 있어서는, 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. 여기서, "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 이상의 독성, 불안정성 또는 자극성이 없는 것을 말한다.In the cosmetic composition, an acceptable carrier may be included in the cosmetic formulation. Herein, "acceptable carrier in cosmetic preparation" means a compound or composition already known and used that may be included in a cosmetic preparation or a compound or composition which will be developed in the future, and which has no toxicity, instability or irritation that is acceptable to the human body upon contact with the skin. Say nothing.
상기 담체는 본 발명의 피부 외용제 조성물에 그것의 전체 중량에 대하여 약 1 중량% 내지 약 99.99 중량%, 바람직하게는 조성물의 중량의 약 90 중량% 내지 약 99.99 중량 %로 포함될 수 있다. 그러나 상기 비율은 본 발명의 피부 외용제 조성물이 제조되는 전술한 바의 제형에 따라 또 그것의 구체적인 적용 부위(얼굴, 목 등)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다.The carrier may be included in the topical skin composition of the present invention from about 1% to about 99.99% by weight, preferably from about 90% to about 99.99% by weight of the composition. However, since the ratio depends on the formulation of the above-described skin external preparation composition of the present invention and its specific application site (face, neck, etc.) or its preferred application amount, the ratio may be viewed in any aspect. It should not be understood as limiting the scope of the invention.
한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. 상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.Meanwhile, examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreen agents, colorants, fragrances, and the like. The compounds / compositions that can be used as the above-mentioned alcohol, oil, surfactant, fatty acid, silicone oil, humectant, humectant, viscous modifier, emulsion, stabilizer, ultraviolet screening agent, coloring agent, fragrance and the like are already known in the art The appropriate substance / composition can be selected and used.
본 발명의 일 구현예로써, 본 발명에 따른 피부 외용제 조성물은 상기 함초 추출물 이외에 글리세린, 부틸렌글리콜, 프로필렌글키롤, 폴리옥시에틸렌 경화피마자유, 에탄올, 트리에탄올아민 등을 포함할 수 있으며, 방부제, 항료, 색소, 정제수 등을 필요에 따라 미량 포함할 수 있다. As an embodiment of the present invention, the external preparation composition for skin according to the present invention may include glycerin, butylene glycol, propyleneglycol, polyoxyethylene hardened castor oil, ethanol, triethanolamine, etc., in addition to the above-mentioned seaweed extract, A trace amount may be included if necessary such as a medicine, a pigment, purified water, and the like.
특히, 상기 피부 외용제 조성물은 본 발명에 특별히 개시된 제조방법 이외에도, 통상적으로 알려진 제조방법을 이용하여, 일반적인 유화 제형 및 가용화 제형의 형태로 제조될 수 있다.In particular, the external preparation composition for the skin may be prepared in the form of general emulsion formulations and solubilized formulations using a conventionally known production method, in addition to the production method specifically disclosed in the present invention.
화장료 조성물로 제조될 경우, 유화 제형의 화장품으로는 영양화장수, 크림, 에센스 등이 있으며, 가용화 제형의 화장품으로는 유연화장수가 있다. 또한, 피부과학적으로 허용가능한 매질 또는 기제를 함유함으로써 피부과학 분야에서 통상적으로 사용되는 국소적용 또는 전신적용할 수 있는 보조제 형태로 제조될 수 있다.When the cosmetic composition is prepared, cosmetics of the emulsion formulations include nutrient cosmetics, creams, essences, etc., and cosmetics of the solubilized formulations include soft cosmetics. In addition, by containing a dermatologically acceptable medium or base, it can be prepared in the form of topical or systemic adjuvants commonly used in the field of dermatology.
또한, 적합한 화장품의 제형으로는, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실스틱의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.In addition, formulations of suitable cosmetics include, for example, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), nonionics obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, for example. It may be provided in the form of a vesicle dispersant in the form of a cream, skin, lotion, powder, ointment, spray or concealed stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
또한, 본 발명의 피부 외용제 조성물은 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일,염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 그리고, 상기의 성분들은 피부과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.In addition, the topical skin composition of the present invention may further comprise fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ions Any commonly used in type or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatology field as other ingredients. In addition, the above components may be introduced in an amount generally used in the dermatology field.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01 - 5 % 중량 백분율, 보다 바람직하게는 0.01 - 3 % 중량 백분율로 배합된다.In addition, any of the above-mentioned components may be blended within the range not to impair the objects and effects of the present invention, but it is preferably 0.01 to 5% by weight based on the total weight, More preferably from 0.01 to 3% by weight.
본 발명의 화장료 조성물의 경우, 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다. In the case of the cosmetic composition of the present invention, it may take the form of a solution, an emulsion, a viscous mixture, and the like. The components included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the extract as an active ingredient. And conventional auxiliaries and carriers such as, for example, stabilizers, solubilizers, vitamins, pigments and flavorings.
본 발명의 기능성 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다. 구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.The functional cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, and includes, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetic, and the like. Specifically, the cosmetic composition of the present invention skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, Formulations of packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트,사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또한, 본 발명은 다른 관점에서, (a) 부활초 식물체의 줄기와 뿌리를 IAA, 제아틴, 및 수크로오스 함유 배지에서 배양하여 캘러스를 유도하는 단계; 및 (b) 상기 캘러스를 함유하는 조성물을 제조하는 단계를 포함하는 부활초 캘러스 추출물을 함유한 피부 외용제 조성물의 제조방법에 관한 것이다.In another aspect, the present invention, (a) inducing the callus by culturing the stems and roots of revival plants in IAA, zeatine, and sucrose-containing medium; And (b) relates to a method for producing a composition for external application for skin containing the revival callus extract comprising the step of preparing a composition containing the callus.
상기 (a)단계에서, 구체적으로는 부활초로부터 캘러스를 유도하기 위해 적절한 배지를 선택할 수 있다. 기술분야에서 캘러스 배양에 일반적으로 사용되고 있는 배지가 있다면, 제한없이 사용가능하다. 식물에서는 일반적으로 MS(Murashige-Skoog)배지, B5배지 등을 주로 사용하고, 일 예로, MS 기초 고체 배지(Murashige and Skoog 1962, Duchefa 사, Cat No. M0221)의 조성(1L기준시)은 NH4NO3 1650 mg, KNO3 1900 mg, CaCl22H2O 440 mg, MgSO47H2O 370 mg, KH2PO4 170 mg, KI 0.83 mg, H3BO3 6.2 mg, MnSO44H2O 22.3mg, ZnSO47H2O 8.6 mg, Na2MoO42H2O 0.25 mg, CuSO45H2O 0.025 mg, CoCl26H2O 0.025 mg, FeSO47H2O 27.8 mg, Na2EDTA2H2O 37.3 mg, Myoinositol 100 mg, Nicotinic acid 0.5 mg, Pyridoxine-HCl 0.5 mg, Thiamine-HCl 0.5 mg, Glycine 2 mg, Sucrose 30000 mg 이다.In step (a), specifically, an appropriate medium may be selected to induce callus from the reeds. If there is a medium generally used in the callus culture in the art, it can be used without limitation. In plants, MS (Murashige-Skoog) medium and B5 medium are generally used.For example, the composition of MS based solid medium (Murashige and Skoog 1962, Duchefa, Cat No. M0221) is NH. 4 NO 3 1650 mg, KNO 3 1900 mg, CaCl 2 2H 2 O 440 mg, MgSO 4 7H 2 O 370 mg, KH 2 PO 4 170 mg, KI 0.83 mg, H 3 BO 3 6.2 mg, MnSO 4 4H 2 O 22.3 mg, ZnSO 4 7H 2 O 8.6 mg, Na 2 MoO 4 2H 2 O 0.25 mg, CuSO 4 5H 2 O 0.025 mg, CoCl 2 6H 2 O 0.025 mg, FeSO 4 7H 2 O 27.8 mg, Na 2 EDTA2H 2 O 37.3 mg, Myoinositol 100 mg, Nicotinic acid 0.5 mg, Pyridoxine-HCl 0.5 mg, Thiamine-HCl 0.5 mg, Glycine 2 mg, Sucrose 30000 mg.
본 발명에 있어서, 부활초로부터 캘러스를 유도하기 위한 배지로써, 상기 MS 기초 고체 배지에 Sucrose 40.0 g/L, Agar 5~10.0 g/L, NAA 0.5 mg/L, BAP 1.0 mg/L를 첨가한 배지를 이용할 수 있다. In the present invention, as a medium for inducing callus from the resurrection flower, Sucrose 40.0 g / L, Agar 5 ~ 10.0 g / L, NAA 0.5 mg / L, BAP 1.0 mg / L was added to the MS-based solid medium Medium can be used.
이것 이외에도, 종래에 부활초 캘러스 유도 배지로써 알려진 다양한 배지들 또한 본 발명에서 적용가능할 것이다. In addition to this, various media conventionally known as resurrection callus induction media will also be applicable in the present invention.
캘러스를 유용물질을 함유하는 배지에서 배양하면, 캘러스가 배지에 첨가된 유용물질을 흡수하여 캘러스 내에 유용물질을 함유하게 되므로, 캘러스는 유래된 식물의 생리 활성 뿐만 아니라, 배지 내 첨가된 유용물질에 의한 생리활성을 나타낼 수 있다. 이러한 캘러스 내 유용물질의 도입은, 상기 유도된 캘러스를 유용물질을 포함하는 배지내에 치상하는 단계를 추가적으로 수행하여 배양된 캘러스에 유용물질을 도입시킬 수도 있다. When the callus is cultured in a medium containing useful substances, the callus absorbs the useful substances added to the medium and thus contains the useful substances in the callus. It can exhibit physiological activity. The introduction of the useful substance in the callus may introduce the useful substance into the cultured callus by additionally performing the step of densifying the induced callus in the medium containing the useful substance.
상기 (b)단계에서, (a)단계에서 얻어지는 캘러스를 분말화하여 조성물에 포함시켜 제조할 수 있다. 구체적으로, 본 발명에 따른 부활초 캘러스 추출물 피부 외용제 조성물에서, 상기 수상성분, 유상성분 이외에 추가적으로, 첨가제 등이 포함될 수 있다. 상기 첨가제로는 알코올, 착색제, 방향제 등이 있다. In step (b), the callus obtained in step (a) may be powdered and included in the composition. Specifically, in addition to the water phase component, the oil phase component, in addition to the water phase component, oil composition may be included in the resurrection callus extract skin external composition according to the present invention. The additives include alcohols, colorants, fragrances and the like.
추가적으로, 본 발명에 따른 피부 외용제 조성물은, 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩, 분말 등의 제형으로 제조될 수 있다.In addition, the topical skin preparation composition according to the invention can be prepared in various forms, for example emulsions, lotions, creams (water-in-oil, water-in-oil, multiphase), solutions, suspensions (anhydrous and aqueous), anhydrous products (Oil and glycol based), gels, masks, packs, powders and the like formulations.
본 발명에 따른 부활초 캘러스 추출물 함유 피부 외용제 조성물의 제조방법은 전술한 제조방법에 한정되는 것은 아니며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 상기 제조방법을 일부 변형시킨 방법으로도 본 발명에 따른 부활초 캘러스 추출물 함유 피부 외용제 조성물을 제조할 수 있다.
The method for preparing the external skin composition of resurrection callus extract containing the present invention according to the present invention is not limited to the above-described manufacturing method, and those skilled in the art to which the present invention pertains may also modify the manufacturing method. It is possible to prepare an external composition for skin resurrection containing callus extract according to the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these examples are for illustrative purposes only and that the scope of the present invention is not construed as being limited by these examples.
부활초 추출물의 제조Preparation of Easter Creeper Extract
실시예Example 1-1: 1-1: 부활초의Resurrection 살균 Sterilization
부활초의 표면을 살균하기 위하여, 부활초의 식물체의 줄기와 뿌리 부분을 적당한 크기로 자른 후 70% 에탄올에 30초간 침지시키고, 0.3% 치아염소산나트륨(Sodium hypochlorite)에 10~15분 진탕하여 살균 후, 멸균수로 세척하였다.In order to sterilize the surface of the resurrection plant, cut the stems and roots of the plant of the resurrection plant to the appropriate size, soak for 30 seconds in 70% ethanol, and shake it for 10-15 minutes with 0.3% sodium hypochlorite, and then sterilize it. Washed with sterile water.
실시예Example 1-2: 1-2: 부활초Resurrection 캘러스Callus 추출물의 제조 Preparation of extract
살균된 부활초의 줄기와 뿌리를 IAA(indole-3-acetic acid) 0.5/L, 제아틴(Zeatin) 0.2/L의 생장조절물질과 수크로오스 30g/L, 겔라이트(Gelite) 2.0g/L를 함유한 MS(Murashinge and Skoog, 1962)배지에 접종한 후 23~27℃의 배양실에서 8주간 배양하여 캘러스를 유도하였다. 유도된 캘러스는 4주 간격으로 계대 배양하여 증식하였다. 증식된 캘러스를 수확하여 깨끗한 티슈로 충분히 수분을 제거한 후 60℃로 2일 동안 건조기에서 건조하였다. 건조된 부활초 캘러스 파우더 100g을 용기에 담고, 정제수 1L를 넣은 후, 65℃에서 2 시간 동안 교반하여 반응시키고, 반응 추출물을 여과하여 1L의 부활초 캘러스 추출물을 제조하였다.
Sterilized stems and roots contained 0.5 / L IAA (indole-3-acetic acid), 0.2 / L Zeatin, 30 g / L sucrose, and 2.0 g / L Gelite. Inoculated in a MS (Murashinge and Skoog, 1962) medium and incubated for 8 weeks in a culture room at 23 ~ 27 ℃ to induce callus. Induced callus was proliferated by subculture at 4 week intervals. The propagated callus was harvested and sufficiently dehydrated with a clean tissue and then dried in a drier at 60 ° C. for 2 days. 100 g of dried resurrection candle callus powder was placed in a container, 1 L of purified water was added thereto, followed by stirring at 65 ° C. for 2 hours, and the reaction extract was filtered to prepare 1 L of resurrection candle callus extract.
비교예Comparative example : : 부활초Resurrection 추출물의 제조 Preparation of extract
부활초 600g 을 정제수 20L를 넣고 열탕 증류기에서 4 내지 8시간 정도, 80 내지 100℃로 가열하여 열수 추출물을 얻었다.
Into the 600 g of the activated vinegar, 20 L of purified water was added and heated to 80 to 100 ° C. for about 4 to 8 hours in a boiling water still to obtain a hot water extract.
실험예 1: 콜라겐 합성 증진 효과Experimental Example 1: Collagen Synthesis Enhancement Effect
인간섬유아세포(Human Skin Fibroblast)를 37℃, 5% CO2 배양기에서 일정한 습도를 유지하는 세포 배양기내에서 10% FBS, Penicillin(50U/ml), Streptomycin(50/ml)를 함유하는 DMEM(Dulbecco's Modified Eagle's Medium, Gibco, USA)으로 배양하여, 1×105개/ml로 24 well plate에 500㎕씩 분주한 다음 24시간 배양하였다. 대조군(DMEM 배지)과 0.1 ~ 10 %의 다양한 농도의 실시예 1의 캘러스 추출물을 함유한 배지를 넣고 48시간동안 37℃, 5% CO2 배양기에서 배양하였다. 48시간 후, 배지의 상층액을 각각 20㎕을 취해 Procollagen Type I C-Peptide EIA Kit(PICP, Takara, Cat No. MK101)를 이용하여 측정함으로써 새로 합성된 콜라겐 양을 측정하였다. 비교예의 부활초 추출물과 상기한 방법과 동일한 방법으로 ㅅ실험하여 결과를 얻었다. Human Skin Fibroblasts at 37 ° C., 5% CO 2 Incubated in Dulbecco's Modified Eagle's Medium, Gibco, USA (DMEM) containing 10% FBS, Penicillin (50 U / ml) and Streptomycin (50 / ml) in a cell incubator with constant humidity, 1 × 10 5 500 µl aliquots were injected into 24 well plates at dogs / ml and incubated for 24 hours. Add the control medium (DMEM medium) and the medium containing the callus extract of Example 1 in various concentrations of 0.1 to 10%, 37 ℃, 5% CO 2 for 48 hours Lt; / RTI > After 48 hours, the amount of newly synthesized collagen was measured by taking 20 μl of the supernatant of the medium and measuring the resultant using a Procollagen Type I C-Peptide EIA Kit (PICP, Takara, Cat No. MK101). The experiment was obtained in the same manner as the above-mentioned method and the resurrection seconds extract of the comparative example to obtain a result.
PICP양은 ng/1×105세포로 환산하였으며, 하기 수학식 1에 따라 계산하여 그 결과는 표 1에 나타나 있다.
PICP amount was converted to ng / 1 × 10 5 cells, and calculated according to Equation 1 below, and the results are shown in Table 1.
[수학식 1][Equation 1]
추출물Resurrection
extract
추출물Resurrection Callus
extract
상기 표 1에서 볼 수 있듯이, 본 발명의 조성물은 부활초 캘러스 추출물의 함량이 증가함에 따라 콜라겐의 생합성량이 증가함을 알 수 있고, 부활초 추출물에 비해서도 본 발명의 조성물이 탁월한 콜라겐 합성 증진 효과를 나타냄을 알 수 있다.
As can be seen in Table 1, the composition of the present invention can be seen that the biosynthesis amount of collagen increases as the content of the revival callus extract is increased, the composition of the present invention has an excellent collagen synthesis promoting effect compared to the revival extract It can be seen that.
실험예Experimental Example 2: 2: MMPMMP -1 생성 억제 효과-1 suppression effect
피부의 주름은 콜라겐의 합성과 분해의 불균형에 기안하는데 보통 피부에서 type I 콜라겐의 합성과 그 분해 효소인 MMP-1이 균형을 이루고 있다. 그러나 광노화된 피부에서는 type I, III 콜라겐의 합성이 저하되고, MMP-1의 활성이 증가된다. 이러한 MMPs(matrix metalloproteinases)는 단백분해효소로 세포외 기질(extracellular matrix)을 분해하는 기능을 나타내며 정상적인 상태에서는 상처치유나 조직재생과정에 관여하는 것으로 알려져 있다. Wrinkles in the skin are due to the imbalance between collagen synthesis and degradation, which is usually balanced by the synthesis of type I collagen and its degradation enzyme, MMP-1. However, in photo-aged skin, the synthesis of type I and III collagen is reduced and the activity of MMP-1 is increased. These matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade the extracellular matrix and are known to be involved in wound healing or tissue regeneration during normal conditions.
본 발명의 조성물이 MMP-1 생성 억제 효과가 있는지를 확인하기 위해, 아래와 같은 실험을 하였다.In order to confirm whether the composition of the present invention has an inhibitory effect on MMP-1 production, the following experiment was carried out.
인간섬유아세포(Human Skin Fibroblast)를 37℃, 5% CO2 배양기에서 일정한 습도를 유지하는 세포 배양기내에서 10% FBS, Penicillin(50U/ml), Streptomycin(50/ml)를 함유하는 DMEM(Dulbecco's Modified Eagle's Medium, Gibco, USA)으로 배양하여, 1×106개/ml로 48 well plate에 분주한 다음 24시간 배양하였다. 대조군(DMEM 배지)과 0.1 ~ 10 %의 다양한 농도의 부활초 캘러스 추출물을 함유한 배지를 넣고 48시간동안 37℃, 5% CO2 배양기에서 배양하였다. 48시간 후, 배지의 상층액을 각각 20㎕을 취해 Matrix Metalloproteinase-1, Biotrack Activity(Amersham, Cat No. RPN2629)를 이용하여 측정함으로써 새로 합성된 MMP-1의 양을 측정한 뒤, mg/ml 환산하여, 하기 수학식 2에 따라 계산하여 그 결과는 표 2에 나타나 있다. 비교예도 상기 실시예와 동일한 방법으로 실험하였다.Human Skin Fibroblasts at 37 ° C., 5% CO 2 1 × 10 6 incubated with DMEM (Dulbecco's Modified Eagle's Medium, Gibco, USA) containing 10% FBS, Penicillin (50 U / ml) and Streptomycin (50 / ml) in a cell incubator with constant humidity. The cells were dispensed in 48 well plates at dogs / ml and incubated for 24 hours. Add a control medium (DMEM medium) and a medium containing the revival callus extract of various concentrations of 0.1 ~ 10%, 37 ℃, 5% CO 2 for 48 hours Lt; / RTI > After 48 hours, 20 μl each of the supernatant of the medium was measured using Matrix Metalloproteinase-1 and Biotrack Activity (Amersham, Cat No. RPN2629) to determine the amount of newly synthesized MMP-1, and then mg / ml. In conversion, it calculates according to following formula (2), and the result is shown in Table 2. Comparative Example was also tested in the same manner as in Example.
[수학식 2]&Quot; (2) "
추출물Resurrection
extract
추출물Resurrection Callus
extract
상기 표 2에서 볼 수 있듯이, 본 발명의 조성물 부활초 캘러스 추출물 함량이 증가함에 따라 MMP-1 생성 억제 효과가 증가함을 알 수 있었으며, 이는 부활초 추출물에 비해서도 훨씬 높은 수준의 MMP-1 생성 억제 효능을 나타냄을 알 수 있다.
As can be seen in Table 2, it was found that the effect of inhibiting the production of MMP-1 increased as the composition of the revival plant callus extract of the present invention is increased, which is much higher than that of the revival plant extract. It can be seen that the efficacy.
실험예Experimental Example 3: 엘라스타제( 3: elastase ( Elastase)Elastase) 억제 효과 Inhibitory effect
기질 1 mM N-succinyl-(Ala)3-p-nitroanilide 200㎕ 에 실시예1에서 제조한 부활초 캘러스 추출물 20 ㎕와 2.5 unit Elastase(Porcie pancreas solution) 10 ㎕를 첨가하여 25℃에서 10 min 동안 반응시킨 후 ELISA reader로 410 nm에서 흡광도를 측정하였다. 하기 수학식 3에 따라 계산하여 그 결과는 표 3에 나타나있다.비교예에서 제조한 부활초 추출물도 상기와 같은 방법을 통해 실험하였다. To 200 µl of the substrate 1 mM N-succinyl- (Ala) 3 -p-nitroanilide, 20 µl of the cauliflower extract prepared in Example 1 and 10 µl of 2.5 unit Elastase (Porcie pancreas solution) were added for 10 min at 25 ° C. After the reaction, the absorbance was measured at 410 nm with an ELISA reader. Calculated according to Equation 3 below and the results are shown in Table 3. The extract of the revival flower prepared in Comparative Example was also tested through the same method.
[수학식 3]&Quot; (3) "
추출물Resurrection
extract
추출물Resurrection Callus
extract
(양성 대조물질)Ursolic acid
(Positive control)
상기 표 3에서 볼 수 있듯이, 본 발명의 조성물은 부활초 캘러스 추출물 함량이 증가함에 따라 Elastase 억제 효과가 증가함을 알 수 있었으며, 이는 세포 증식능에 효과가 있음을 의미한다.As can be seen in Table 3, the composition of the present invention was found to increase the inhibitory effect of Elastase with increasing the content of revival callus extract, which means that the effect on the cell proliferation ability.
실험예 4:ABTS Radical Scavenging ActivityExperimental Example 4: ABTS Radical Scavenging Activity
ABTS radical을 이용한 항산화능의 측정은 potassium persulfate와의 반응에 의해 생성된 ABTS free radical이 추출물 내의 항산화 물질에 의해 제거되어 radical 특유의 색인 청록색이 탈색되는 것을 이용한 방법으로 Van den Berg 등의 방법을 변형하여 측정하였다.Antioxidant activity using ABTS radical was measured by removing the ABTS free radical produced by the reaction with potassium persulfate by the antioxidant in the extract and decolorizing the blue color of the index. Measured.
1.0 mM의 AAPH(2,2'-azo-bis 2-amidinopropanedeihydrochloride)는 100 mM PBS buffer에 녹인 2.5 mM ABTS(2,2'-azino-bis 3-ethylbenzenothiazolin-6-sulfonic acid)와 혼합한 후 68℃ 의 항온조에서 12분 동안 반응시켰다. 농도별로 희석한 실시예1의 부활초 캘러스 추출물 20㎕ 와 980㎕ ABTS 용액을 37℃ water bath에서 10분간 반응시키면서 734 nm에서 감소하는 흡광도의 정도를 측정하였으며 이때 양성대조군은 Trolox 0.1 % 을 사용하였다. ABTS radical 소거능은 다음의 수학식 4에 따라 계산하였으며, 결과는 표 4와 같았다. 비교예에서 제조한 부활초 추출물도 동일한 방법으로 실험하였다.1.0 mM AAPH (2,2'-azo-bis 2-amidinopropanedeihydrochloride) was mixed with 2.5 mM ABTS (2,2'-azino-bis 3-ethylbenzenothiazolin-6-sulfonic acid) dissolved in 100 mM PBS buffer. The reaction was carried out for 12 minutes in a thermostat bath. The concentration of absorbance decreased at 734 nm was measured by reacting 20 µl of cultivated callus extract of Example 1 diluted with different concentrations and 980 µl ABTS solution in a 37 ° C water bath for 10 minutes. . ABTS radical scavenging ability was calculated according to the following equation (4), the results are shown in Table 4. The eastern herb extract prepared in Comparative Example was also tested in the same manner.
[수학식 4]&Quot; (4) "
(항산화효과)ABTS radical scavenging activity (%)
(Antioxidative effect)
추출물Resurrection
extract
추출물Resurrection Callus
extract
(양성 대조물질)Trolox
(Positive control)
상기 표 4에서 볼 수 있듯이, 본 발명의 조성물은 부활초 캘러스 추출물 함량이 증가함에 따라 항산화능이 증가함을 알 수 있었으며, 양성 대조물질과 유사한 수준 정도로 항산화능이 있음을 알 수 있다.
As can be seen in Table 4, the composition of the present invention was found to increase the antioxidant activity as the content of the revival callus extract, it can be seen that the antioxidant capacity to a similar level as the positive control.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.
While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
Claims (9)
Resurrection Candle ( Myrothamnus flabellifolia ) Skin external preparation composition containing the callus extract as an active ingredient.
The method of claim 1, wherein the resurrection candle Callus extract is an external composition for skin, characterized in that it contains 0.1 to 10% by weight relative to the total weight of the composition.
The composition for external application for skin according to claim 1, wherein the revival callus extract is powdered and contained in the composition.
The external preparation composition for skin according to claim 1, wherein the external preparation composition for skin aging is used.
The external preparation composition for skin according to claim 1, wherein the external preparation composition for skin elasticity is used.
The external preparation composition for skin according to claim 1, wherein the external preparation composition for skin wrinkle prevention and skin wrinkle improvement is used.
According to claim 1, wherein the topical skin composition is an external composition for skin, characterized in that the composition having an antioxidant capacity.
The external preparation composition for skin according to claim 1, wherein the external preparation composition for skin has collagen synthesis enhancing ability.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110028322A KR101305698B1 (en) | 2011-03-29 | 2011-03-29 | Skin External Composition Containing Myrothamnus flabellifolia Callus Extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110028322A KR101305698B1 (en) | 2011-03-29 | 2011-03-29 | Skin External Composition Containing Myrothamnus flabellifolia Callus Extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120110453A true KR20120110453A (en) | 2012-10-10 |
| KR101305698B1 KR101305698B1 (en) | 2013-09-09 |
Family
ID=47281273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110028322A KR101305698B1 (en) | 2011-03-29 | 2011-03-29 | Skin External Composition Containing Myrothamnus flabellifolia Callus Extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101305698B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2997853A1 (en) * | 2012-11-09 | 2014-05-16 | Oreal | Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin |
| CN109223660A (en) * | 2018-11-22 | 2019-01-18 | 武汉跃莱健康产业有限公司 | A kind of shining face is anti-ageing to peptide face cream and preparation method thereof |
| CN111182906A (en) * | 2017-08-07 | 2020-05-19 | 玫琳凯有限公司 | Topical skin compositions for treating erythema or skin inflammation |
| KR102752144B1 (en) * | 2023-09-13 | 2025-01-10 | 그린코스 주식회사 | Cosmetic composition that promotes the growth of eyelash length and density and strengthens eyelashes |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240057426A (en) | 2021-09-03 | 2024-05-02 | 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 | Use of extracts of Myrothamnus species to promote hair growth |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2819414A1 (en) * | 2001-01-15 | 2002-07-19 | Cognis France Sa | COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS COMPRISING EXTRACTS FROM PLANTS RESOURCING |
| KR100637342B1 (en) * | 2003-10-30 | 2006-10-23 | 윤성용 | Use of callus for natural cosmetic development |
-
2011
- 2011-03-29 KR KR1020110028322A patent/KR101305698B1/en active IP Right Grant
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2997853A1 (en) * | 2012-11-09 | 2014-05-16 | Oreal | Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin |
| CN111182906A (en) * | 2017-08-07 | 2020-05-19 | 玫琳凯有限公司 | Topical skin compositions for treating erythema or skin inflammation |
| EP3664812A4 (en) * | 2017-08-07 | 2021-04-28 | Mary Kay Inc. | Topical skin compositions for treating erythema or skin inflammation |
| CN109223660A (en) * | 2018-11-22 | 2019-01-18 | 武汉跃莱健康产业有限公司 | A kind of shining face is anti-ageing to peptide face cream and preparation method thereof |
| KR102752144B1 (en) * | 2023-09-13 | 2025-01-10 | 그린코스 주식회사 | Cosmetic composition that promotes the growth of eyelash length and density and strengthens eyelashes |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101305698B1 (en) | 2013-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101914157B1 (en) | Cosmetic composition comprising camellia sinensis constituents | |
| KR101740097B1 (en) | Anti-inflammation and Anti-aging composition for skin external application comprising Leontopodium alpinum Cell Culture Extract and Methods for preparing the Same | |
| KR101533947B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Paeonia suffruticosa Plant Placenta Cell Cultures Extracts | |
| KR101549299B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Lotus Plant Placenta Cell Cultures Extracts | |
| KR101838354B1 (en) | Anti-aging composition for skin external application comprising Camellia japonica Plant Cell Culture Extract and Method for Preparing the Same | |
| KR101305698B1 (en) | Skin External Composition Containing Myrothamnus flabellifolia Callus Extract | |
| KR101696021B1 (en) | Anti-aging and Skin- Astriction composition for skin external application comprising Aster sphathulifolius Maxim. Cell Culture Extract and Methods for preparing the Same | |
| KR101619571B1 (en) | Anti-aging Composition for Skin External Application Comprising Magnolia Placenta Culture Extracts | |
| KR20150065560A (en) | Anti-aging Composition Including Nelumbo Nucifera Callus Extract | |
| KR101143717B1 (en) | Composition for Skin External Application Comprising Extract of Nelumbo Nucifera Callus | |
| KR20140095122A (en) | A composition for inhibiting degradation of collagen or promoting synthesis of collagen comprising barley extract or eriodictyol | |
| KR20160021371A (en) | Anti-inflammation and Anti-aging composition for skin external application comprising Narcissus tazetta Cell Culture Extract and Methods for preparing the Same | |
| KR101693923B1 (en) | Anti-inflammation and Anti-aging composition for skin external application comprising Zostera marina Cell Culture Extract and Methods for preparing the Same | |
| KR101533217B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Nymphaea tetragona Plant Placenta Cell Cultures Extracts | |
| KR101334485B1 (en) | A Skin External Composition Containing Callus Extract Drived from Rhizophora Mangle | |
| KR101467033B1 (en) | Composition for Skin External Application Comprising Culture Extract of Soy Bean Placenta | |
| KR101427027B1 (en) | A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis | |
| KR101852252B1 (en) | Method for culturing Lilium Candidum Cell and Functional skin external application comprising Lilium Candidum Cell Culture Extract | |
| KR101619710B1 (en) | Anti-aging Composition for Skin External Application Comprising Liriodendron tulipifera Placenta Culture Extracts | |
| KR101673664B1 (en) | Anti-aging, Anti-inflammatory and Skin-Astriction composition for skin external application comprising Artemisia annua L. Cell Culture Extract and Methods for preparing the Same | |
| KR101619711B1 (en) | Anti-aging Composition for Skin External Application Comprising Schizandra chinensis Placenta Culture Extracts | |
| KR101291460B1 (en) | A Skin External Composition Containing Callus Extract Drived from Eleutherococcus koreanum Nakai | |
| TWI767559B (en) | Extract of white and dedifferentiated cells and uses thereof and cosmetic products containing the same | |
| KR101457784B1 (en) | A Skin External Composition Containing Callus Extract Derived from Bupleurm falcatum L. | |
| KR101619712B1 (en) | Anti-aging Composition for Skin External Application Comprising Eupomatia laurina Placenta Culture Extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20110329 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130129 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130827 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130902 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20130902 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction | ||
| FPAY | Annual fee payment |
Payment date: 20170620 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170620 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180802 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180802 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20190619 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190619 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210630 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220630 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230627 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240624 Start annual number: 12 End annual number: 12 |